Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in breastfeeding women with MS/CIS
NCT04998851Phase 4Completed
- Sponsor
- Roche
- Start
- Sep 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS) and clinically isolated syndrome (CIS), sponsored by Roche. Primary endpoints: Percentage of Infants With B Cell Levels (CD19+ Cells) Below the Lower Limit of Normal at 30 days and Estimated Average Oral Daily Infant Dosage at 60 days. Started Sep 2021; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT04998851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998851.